T1	PROC 46 77	Estudio de eficacia y seguridad
T2	CHEM 115 126	secukinumab
#1	AnnotatorNotes T2	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 153 172	psoriasis en placas
#2	AnnotatorNotes T3	C0263361; Psoriasis vulgaris; Disease or Syndrome
T4	PROC 215 287	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo
T5	PROC 320 368	demostrar la eficacia, seguridad y tolerabilidad
T6	CHEM 399 410	secukinumab
#3	AnnotatorNotes T6	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	DISO 478 497	psoriasis en placas
#4	AnnotatorNotes T7	C0263361; Psoriasis vulgaris; Disease or Syndrome
T8	DISO 553 562	psoriasis
#5	AnnotatorNotes T8	C0033860; Psoriasis; Disease or Syndrome
T9	DISO 575 620	zonas rojas, engrosadas, escamosas de la piel
T10	ANAT 616 620	piel
#6	AnnotatorNotes T10	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T11	DISO 648 667	Psoriasis en placas
#7	AnnotatorNotes T11	C0263361; Psoriasis vulgaris; Disease or Syndrome
T12	DISO 775 802	Psoriasis crónica en placas
T13	PROC 840 853	diagnosticada
#8	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	PROC 866 880	aleatorización
#9	AnnotatorNotes T14	C0034656; Randomization; Research Activity
T15	PROC 896 917	tratamiento sistémico
T16	PROC 984 993	protocolo
#10	AnnotatorNotes T16	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T17	PROC 1018 1027	protocolo
#11	AnnotatorNotes T17	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T18	DISO 1066 1075	psoriasis
#12	AnnotatorNotes T18	C0033860; Psoriasis; Disease or Syndrome
T19	DISO 1082 1109	psoriasis crónica en placas
T20	DISO 1119 1162	psoriasis pustulosa, eritrodérmica y gutata
#13	AnnotatorNotes T20	C0152081; Pustular psoriasis; Disease or Syndrome + C0748052; Erythrodermic psoriasis; Disease or Syndrome + C0343052; Guttate psoriasis; Disease or Syndrome
T21	CHEM 1347 1353	IL-17A
T22	PROC 1182 1196	aleatorización
#14	AnnotatorNotes T22	C0034656; Randomization; Research Activity
T23	PROC 1213 1225	tratamientos
#15	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	CHEM 1260 1271	secukinumab
#16	AnnotatorNotes T24	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T25	CHEM 1300 1317	fármaco biológico
#17	AnnotatorNotes T25	C0005515; Biological Factors; Biologically Active Substance (?)
T26	CHEM 1359 1376	receptor de IL-17
T27	PROC 1490 1499	protocolo
#18	AnnotatorNotes T27	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T28	PROC 1524 1533	protocolo
#19	AnnotatorNotes T28	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T29	PROC 372 395	inyecciones subcutáneas
T30	CHEM 1273 1279	AIN457
#20	AnnotatorNotes T30	C3179548; AIN 457; Amino Acid, Peptide, or Protein · Immunologic Factor
T31	Date 13 17	2015
T32	DEVI 85 103	jeringa precargada
#21	AnnotatorNotes T32	C1609474; Prefilled Syringe; Medical Device
T33	Dose 107 111	2 ml
T34	Dose 128 134	300 mg
T35	LIVB 139 148	pacientes
#22	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Duration 292 302	52 semanas
T37	Route 384 395	subcutáneas
#23	AnnotatorNotes T37	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T38	DEVI 415 435	jeringas precargadas
#24	AnnotatorNotes T38	C1609474; Prefilled Syringe; Medical Device
T39	Dose 439 452	2 ml (300 mg)
T41	LIVB 456 473	pacientes adultos
#25	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T43	LIVB 696 703	Hombres
#26	AnnotatorNotes T43	C0025266; Male population group; Population Group
T44	LIVB 706 713	mujeres
#27	AnnotatorNotes T44	C0043210; Woman; Population Group
T45	Age 717 733	al menos 18 años
T46	Duration 785 792	crónica
#28	AnnotatorNotes T46	C0205191; chronic; Temporal Concept
T47	Duration 821 837	al menos 6 meses
T49	Neg_cue 1076 1081	salvo
T50	Duration 1092 1099	crónica
#29	AnnotatorNotes T50	C0205191; chronic; Temporal Concept
T51	Date 1203 1209	actual
T52	LIVB 1379 1424	Mujeres embarazadas o en periodo de lactancia
#30	AnnotatorNotes T52	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T53	PHYS 1415 1424	lactancia
#31	AnnotatorNotes T53	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T42	PHYS 1387 1398	embarazadas
#32	AnnotatorNotes T42	C0032961; Pregnancy; Organism Function
A1	Assertion T19 Negated
A2	Population_data T41 Age
A3	Assertion T23 Contraindicated
A4	Status T24 History_of
A5	Status T30 History_of
A6	Status T25 History_of
#33	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#34	AnnotatorNotes T4	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#35	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity
#36	AnnotatorNotes T29	C0021499; Subcutaneous Injections; Therapeutic or Preventive Procedure
#37	AnnotatorNotes T51	C0521116; Current (present time); Temporal Concept 
#38	AnnotatorNotes T21	C1705947; Interleukin-17A; Amino Acid, Peptide, or Protein · Receptor 
#39	AnnotatorNotes T26	C1721056; Receptors, Interleukin-17; Amino Acid, Peptide, or Protein · Receptor
T48	Spec_cue 921 930	Se pueden
T54	Quantifier_or_Qualifier 939 944	otros
A7	Assertion T54 Speculated
T55	CONC 945 967	criterios de inclusión
A8	Assertion T55 Speculated
#40	AnnotatorNotes T55	C1512693; Inclusion Criteria; Qualitative Concept
R1	Speculation Arg1:T48 Arg2:T54	
R2	Speculation Arg1:T48 Arg2:T55	
R3	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T54	
T56	Spec_cue 1427 1436	Se pueden
T57	Quantifier_or_Qualifier 1445 1450	otros
A9	Assertion T57 Speculated
T58	CONC 1451 1473	criterios de exclusión
A10	Assertion T58 Speculated
#41	AnnotatorNotes T58	C0680251; Exclusion Criteria; Functional Concept
R4	Speculation Arg1:T56 Arg2:T57	
R5	Speculation Arg1:T56 Arg2:T58	
R6	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T57	
R7	Negation Arg1:T49 Arg2:T19	
#42	AnnotatorNotes T54	C0205394; Other; Qualitative Concept
R8	Has_Dose_or_Strength Arg1:T2 Arg2:T33	
R9	Has_Dose_or_Strength Arg1:T2 Arg2:T34	
R10	Used_for Arg1:T32 Arg2:T2	
R11	Experiences Arg1:T35 Arg2:T2	
R12	Experiences Arg1:T35 Arg2:T3	
T59	Quantifier_or_Qualifier 176 192	moderada a grave
#43	AnnotatorNotes T59	C1299393; Moderate to severe; Qualitative Concept
T60	Quantifier_or_Qualifier 501 517	moderada a grave
#44	AnnotatorNotes T60	C1299393; Moderate to severe; Qualitative Concept
R13	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T60	
R14	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T59	
R15	Has_Duration_or_Interval Arg1:T4 Arg2:T36	
R16	Used_for Arg1:T6 Arg2:T29	
R17	Has_Route_or_Mode Arg1:T6 Arg2:T37	
R18	Used_for Arg1:T38 Arg2:T6	
R19	Has_Dose_or_Strength Arg1:T6 Arg2:T39	
R21	Experiences Arg1:T41 Arg2:T29	
R22	Experiences Arg1:T41 Arg2:T7	
R23	Causes Arg1:T8 Arg2:T9	
R24	Location_of Arg1:T10 Arg2:T8	
R25	Location_of Arg1:T10 Arg2:T9	
R26	Has_Age Arg1:T43 Arg2:T45	
R27	Has_Age Arg1:T44 Arg2:T45	
T61	PROC 762 771	selección
#45	AnnotatorNotes T61	C0242802; Patient Selection; Research Activity
R28	Overlap Arg1:T61 Arg2:T45	
R29	Has_Duration_or_Interval Arg1:T12 Arg2:T46	
R30	Has_Duration_or_Interval Arg1:T12 Arg2:T47	
R31	Before Arg1:T13 Arg2:T14	
#46	AnnotatorNotes T15	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R32	Has_Duration_or_Interval Arg1:T19 Arg2:T50	
R33	Overlap Arg1:T18 Arg2:T22	
R34	Overlap Arg1:T19 Arg2:T22	
R35	Overlap Arg1:T20 Arg2:T22	
T62	PROC 1170 1179	selección
#47	AnnotatorNotes T62	C0242802; Patient Selection; Research Activity
R36	Overlap Arg1:T18 Arg2:T62	
R37	Overlap Arg1:T19 Arg2:T62	
R38	Overlap Arg1:T20 Arg2:T62	
R39	Overlap Arg1:T23 Arg2:T51	
T63	Quantifier_or_Qualifier 1318 1376	directamente dirigido contra IL-17A o el receptor de IL-17
A11	Status T63 History_of
R40	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T63	
R41	Experiences Arg1:T52 Arg2:T42	
R42	Experiences Arg1:T52 Arg2:T53	
R43	Before Arg1:T12 Arg2:T14	
#48	AnnotatorNotes T57	C0205394; Other; Qualitative Concept
T64	Route 908 917	sistémico
R44	Has_Route_or_Mode Arg1:T15 Arg2:T64	
#49	AnnotatorNotes T64	C0205373; Systemic; Functional Concept
A12	Experiencer T35 Patient
A13	Experiencer T41 Patient
A14	Experiencer T44 Patient
A15	Experiencer T43 Patient
A16	Experiencer T52 Patient
A17	Status T15 Future
